DGF clinical trials at UCSF
1 research study open to eligible people
Delayed graft function (DGF) is a condition where a kidney does not work right after transplant. UCSF is testing a medicine called Ravulizumab to see if it helps kidneys work better after surgery. This study includes adults at high risk of DGF after kidney transplants.
Showing trials for
Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
open to eligible people ages 18 years and up
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
San Francisco, California and other locations
Last updated: